What does Pfizer's merger mean for drug development?

What does Pfizer's merger mean for drug development?

Another highlight of Allergan's pipeline is abicipar pegol, an anti-angiogenic VEGF inhibitor that is in phase 3 trials for wet age-related macular degeneration and in phase 2 development for diabetic macular oedema. Saunders pointed to the new Pfizer's ability to sell Allergan's lega...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 2016-01, Vol.387 (10013), p.14-15
Main Author: Mullard, Asher
Format: Article
Language:eng
Subjects:
Acquisitions & mergers
Drug Discovery
Drug Industry
Humans
Internal Medicine
Pharmaceutical industry
Pharmaceuticals
R&D
Research & development
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Another highlight of Allergan's pipeline is abicipar pegol, an anti-angiogenic VEGF inhibitor that is in phase 3 trials for wet age-related macular degeneration and in phase 2 development for diabetic macular oedema. Saunders pointed to the new Pfizer's ability to sell Allergan's legacy drugs in Japan, the second largest pharmaceutical market in the world, and China, a huge emerging market, as key opportunities for growth.
ISSN:0140-6736
1474-547X